(NASDAQ: ASMB) Assembly Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.25%.
Assembly Biosciences's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast ASMB's revenue for 2026 to be $759,674,197, with the lowest ASMB revenue forecast at $630,526,937, and the highest ASMB revenue forecast at $888,475,328. On average, 6 Wall Street analysts forecast ASMB's revenue for 2027 to be $893,015,741, with the lowest ASMB revenue forecast at $319,254,145, and the highest ASMB revenue forecast at $1,614,086,248.
In 2028, ASMB is forecast to generate $1,360,291,419 in revenue, with the lowest revenue forecast at $748,251,903 and the highest revenue forecast at $1,998,901,512.